Skip to content

US · ACRS · BIOTECHNOLOGY

Aclaris Therapeutics, Inc. (ACRS) intrinsic value and stock valuation

$3.44as of 2026-11-21 · Mkt cap 888.26M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aclaris Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ACRS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ACRS’s statements →

Aclaris Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Wayne, PA 19087 aclaristx.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$7.83M+3.9% 5y CAGRd
20132025
Net income
-$-64.92M
20132025
Free cash flow
-$-47.11M
20132025
Total equity
$103.1M+22.3% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$7.83M$18.7M$31.3M$29.8M$6.76M
Operating income-$-76.38M-$-141.93M-$-97.36M-$-89.85M-$-89.72M
Net income-$-64.92M-$-132.06M-$-88.48M-$-86.91M-$-90.86M
EPSd-$-529.27K-$-1.71M-$-1.27M-$-1.33M-$-1.6M
Operating cash flow-$-47.11M-$-20.07M-$-78.33M-$-67.57M-$-52.13M
Capital expenditure-$-110K-$-120K-$-1.31M-$-600K-$-310K
Free cash flow-$-47.11M-$-20.2M-$-79.63M-$-68.17M-$-52.44M
Total assets$160.5M$220.3M$197.4M$254.6M$251.2M
Total debt$2.12M$0.00$430K$680K$690K
Net debt-$-17.84M-$-24.57M-$-39.45M-$-44.59M-$-26.66M
Total equity$103.1M$155.6M$157.2M$197.6M$197.3M
Cash and short-term investments$90.8M$113.6M$119.1M$217.6M$191.4M
Income statement
20252024202320222021
Revenue$7.83M$18.7M$31.3M$29.8M$6.76M
Cost of revenue$2.09M$2.79M$18.1M$12M$4.71M
Gross profit$5.74M$15.9M$13.2M$17.8M$2.05M
Research and development expenses$52.7M$33.6M$98.4M$77.8M$43.8M
Selling, general and administrative expenses$22M$22.2M$31.1M$25.1M$23.6M
Other expenses$7.49M$102.1M-$-18.96M$4.7M$24.3M
Operating expenses$82.1M$157.9M$110.5M$107.7M$91.8M
Cost and expenses$84.2M$160.7M$128.6M$119.6M$96.5M
Interest income$7.64M$7.95M$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$450K$810K$860K$800K$920K
Ebitda-$-64.47M-$-51.72M-$-115.45M-$-84.36M-$-64.46M
Operating income-$-76.38M-$-141.93M-$-97.36M-$-89.85M-$-89.72M
Total other income/expenses, net$11.5M$9.87M$8.51M$2.95M-$-1.14M
Income before tax-$-64.92M-$-132.06M-$-88.85M-$-86.91M-$-90.86M
Income tax expense$0.00$0.00-$-370K$0.00$0.00
Net income-$-64.92M-$-132.06M-$-88.48M-$-86.91M-$-90.86M
Weighted average shares outstanding$122.7M$77.3M$69.8M$65.2M$56.7M
Weighted average diluted shares outstanding$122.7M$77.3M$69.8M$65.2M$56.7M
Balance sheet
20252024202320222021
Cash and short-term investments$90.8M$113.6M$119.1M$217.6M$191.4M
Net receivables$5.57M$320K$300K$480K$620K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$151.4M$126M$128.9M$231.6M$205M
Property, plant and equipment, net$0.00$1.01M$1.62M$1.1M$1.33M
Goodwill and intangible assets$0.00$0.00$270K$6.97M$7.05M
Long-term investments$60.6M$90.3M$62.8M$12.2M$34.2M
Total non-current assets$9.1M$94.4M$68.6M$23.1M$46.2M
Total assets$160.5M$220.3M$197.4M$254.6M$251.2M
Accounts payable$13.2M$4.69M$8.88M$10.4M$9.98M
Short-term debt$550K$0.00$430K$680K$690K
Deferred revenue$3.94M$3.89M$0.00$0.00$0.00
Total current liabilities$28.6M$31.6M$31M$21.9M$22.9M
Long-term debt$1.56M$0.00$0.00$0.00$0.00
Deferred revenue, non-current$16.2M$20M$0.00$0.00$0.00
Total non-current liabilities$28.7M$33.2M$9.27M$35M$30.9M
Capital lease obligations$1.56M$0.00$430K$680K$690K
Total liabilities$57.4M$64.8M$40.2M$57M$53.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-967.78M-$-902.86M-$-770.8M-$-682.32M-$-595.41M
Accumulated other comprehensive income (loss)$610K$100K-$-110K-$-900K-$-220K
Total equity$103.1M$155.6M$157.2M$197.6M$197.3M
Total investments$131.4M$179.3M$142M$184.5M$198.3M
Total debt$2.12M$0.00$430K$680K$690K
Net debt-$-17.84M-$-24.57M-$-39.45M-$-44.59M-$-26.66M
Cash flow statement
20252024202320222021
Net income-$-64.92M-$-132.06M-$-88.48M-$-86.91M-$-90.86M
Depreciation and amortization$450K$810K$860K$800K$920K
Stock-based compensation$12.4M$10.9M$20.5M$15M$14.1M
Change in working capital$2.67M$10.9M$9.39M-$-1.2M-$-1.34M
Accounts receivable$6.14M-$-20K$190K$140K$150K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$8.45M-$-4.19M-$-1.47M$370K$3.65M
Net cash provided by operating activities-$-47.11M-$-20.07M-$-78.33M-$-67.57M-$-52.13M
Investments in property, plant and equipment-$-110K-$-120K-$-1.31M-$-600K-$-310K
Acquisitions, net$0.00$0.00$0.00-$-13.23M$167.3M
Net cash used for investing activities$48.4M-$-69.77M$46.2M$12.6M-$-167.63M
Common stock issued$0.00$74.9M$26.7M$72.7M$238.2M
Common stock repurchased-$-450K$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-5.86M$74.5M$26.7M$72.9M$225.1M
Net change in cash-$-4.61M-$-15.31M-$-5.4M$17.9M$5.29M
Cash at end of period$20M$24.6M$39.9M$45.3M$27.4M
Operating cash flow-$-47.11M-$-20.07M-$-78.33M-$-67.57M-$-52.13M
Capital expenditure-$-110K-$-120K-$-1.31M-$-600K-$-310K
Free cash flow-$-47.11M-$-20.2M-$-79.63M-$-68.17M-$-52.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aclaris Therapeutics, Inc.

        Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

        CEO
        Neal S. Walker
        Employees
        73
        Beta
        0.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Aclaris Therapeutics, Inc. (ACRS)?

        Aclaris Therapeutics, Inc. (ACRS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ACRS undervalued?

        ACRS trades at a price of $3.44 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.